Cohance Lifesciences 
Dealstreet

SAM acts on Cohance Lifesciences ₹3,093 on-market share sale

The transaction team was led by Ambarish.

Bar & Bench

Shardul Amarchand Mangaldas & Co has acted as the legal advisor for an on-market sale of 8.93% shareholding in Cohance Lifesciences Limited for ₹3,093 crore by Jusmiral Holdings Limited.

The transaction team was led by Ambarish (Partner), with support from Krishaal Morjaria (Principal Associate) and Varun Natarajan (Senior Associate).

Kanwardeep Singh Kapany (Counsel) advised on Securities law aspects.

Ameya Gokhale (Partner) and Kriti Kalyani (Principal Associate) also provided inputs.

Ambarish

SAM has earlier advised Advent in its control acquisition of Suven Pharmaceuticals Limited by way of a share purchase and mandatory open offer. SAM also advised on the subsequent merger of Cohance with and into Suven, upon which Suven was renamed as Cohance. 

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Also Read

Delhi HC's Justice Sanjeev Narula holds court on Sunday; grants parole to rape convict whose sister died in the morning

ADR no longer an alternative, but essential: Arjun Ram Meghwal at BICC launch

Peer review of summons issued to lawyers unworkable; Supreme Court issued adequate guidelines: Arvind Datar

Courting controversy: In-house and out of privilege

Market data analysis firm moves Kerala court against Groww for passing off

SCROLL FOR NEXT